COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation
27/05/2024
La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation L’examen prioritaire accordé par la FDA est [...]
Changes to the Roche Enlarged Corporate Executive Committee
27/05/2024
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry joined Genentech in [...]
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
25/05/2024
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of [...]
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
25/05/2024
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + [...]
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
25/05/2024
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3 [...]
Merus : publication d’un résumé sur l’association pétosemtamab + pembrolizumab dans le traitement de 1re ligne du CETC r/m lors de l’édition 2024 du congrès ASCO®
25/05/2024
- Taux de réponse de 60 % observé auprès de 10 patients évaluables - Profil d’innocuité favorable chez 26 patients recrutés à la date de clôture du résumé, sans aucune observation de chevauchement significatif des [...]
Merus annonce la publication des résumés qui seront présentés à la réunion annuelle 2024 de l’ASCO®
25/05/2024
Présentation orale rapide du MCLA-145 en monothérapie et en association avec le pembrolizumab : 2 juin 2024, 11 h 30-13 h, heure centrale Présentation sur affiche du MCLA-129 dans le cancer bronchique non à petites [...]
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
25/05/2024
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today [...]
Halo Dental Technologies Showcase Their Digital Mirror at Montreal-based JDIQ Annual Conference
25/05/2024
At the largest bilingual dental convention in North America, Halo will showcase the first-of-its-kind digital dental mirror at its home-city event, for leading dentists and hygienists in Canada. MONTREAL, May 24, 2024 ( [...]
Halo Technologies Dentaires présente son Miroir Numérique à la conférence annuelle JDIQ à Montréal
25/05/2024
Lors de la plus grande convention dentaire bilingue en Amérique du Nord, Halo présentera son miroir dentaire numérique unique en son genre lors de cet événement dans sa ville natale, destiné aux dentistes et hygiénistes [...]
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
24/05/2024
FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial [...]
Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
24/05/2024
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“ Rakovina ” or the “ Company ”) (TSX-V: RKV) announces that in accordance with [...]
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
24/05/2024
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced the presentation of three abstracts that highlights data from [...]
R1 RCM to Present at the 2024 Jefferies Global Healthcare Conference
24/05/2024
MURRAY, Utah, May 24, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today [...]
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q
24/05/2024
ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was [...]
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
24/05/2024
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte [...]
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/05/2024
SAN DIEGO, May 24, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from [...]
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
24/05/2024
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced that the US Food and Drug Administration (FDA) has granted Fast [...]
Appointment of new CFO
24/05/2024
ANNOUNCEMENT NO. 269 Appointment of new CFO The board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company [...]

Pages